Any time that information about a patient's medication is communicated, there is a potential for error that occurs because of misinterpretation of abbreviations, acronyms, and dose designations. In the following discussion, corrective approaches for reducing the use of error-prone terms will be reviewed. Terms on the "Do Not Use" list are identified and the rationale for using "Tall Man" letters is addressed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/NOR.0b013e3181a50a84 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Mental health remains among the top 10 leading causes of disease burden globally, and there is a significant treatment gap due to limited resources, stigma, limited accessibility, and low perceived need for treatment. Problem Management Plus, a World Health Organization-endorsed brief psychological intervention for mental health disorders, has been shown to be effective and cost-effective in various countries globally but faces implementation challenges, such as quality control in training, supervision, and delivery. While digital technologies to foster mental health care have the potential to close treatment gaps and address the issues of quality control, their development requires context-specific, interdisciplinary, and participatory approaches to enhance impact and acceptance.
View Article and Find Full Text PDFInvestigation of the Effect of Lymphedema Self-Care Patient School on Functionality, Quality of Life, Lymphedema Volume, and Body Value in Patients with Lower Extremity Lymphedema: A Quasi-Experimental Study.
Lymphology
January 2024
Palliative Care, Ege University Hospital Faculty of Medicine, Izmir, Turkey.
This study examined the effect of lymphedema self-care patient school education on patient functionality, quality of life, body value, and lymphedema volume in patients with lower extremity lymphedema. The study utilized a single-group quasi-experimental design. The study sample included 21 patients with primary and secondary lower extremity lymphedema.
View Article and Find Full Text PDFCurrent Role of Pneumatic Compression Therapy in Lymphedema Care: A Scoping Review of Persistent Debates and New Applications.
Lymphology
January 2024
Vascular Medicine Unit, Cholet Hospital, Cholet, France.
Access to trained lymphedema care providers remains limited making patient-driven management solutions essential. One such option, sequential intermittent pneumatic compression (IPC), has gained traction as a supportive tool for lymphedema management. While newer IPC devices and innovative applications are being introduced to the market, questions regarding the safety and efficacy of this technology persist.
View Article and Find Full Text PDFUnderstanding of Clinical Trials Among Patients With Cancer and Their Relatives.
JAMA Netw Open
January 2025
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Importance: Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants' decision-making is critical for enhancing trial recruitment.
Objective: To evaluate the attitudes of patients with cancer and their relatives toward clinical trial participation, identifying key barriers and motivators that affect their willingness to engage in such trials.
Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial.
Circulation
January 2025
Department of Angiology, University Hospital Zurich, University of Zurich, Switzerland.
Background: In patients with post-thrombotic syndrome (PTS), stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial tested whether daily aspirin 100 mg plus rivaroxaban 20 mg is superior to rivaroxaban 20 mg alone to prevent stent thrombosis within 6 months after stent placement for PTS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!